Description: BRIN-BD11 is a hybrid cell line formed by the electrofusion of a primary culture of NEDH rat pancreatic islets with RINm5F (a cell line derived from a NEDH rat insuliinoma). BRIN-BD11 has been shown to be tumourigenic when transplanted into a SCID mouse host. BRIN-BD11 has been mycoplasma eradicated at ECACC and the stocks available for supply have undergone a further 10 passages without detection of mycoplasma. The cell line has applications in the study of pancreatic beta cell function.

Also Known As:

Species: Rat

Tissue: Pancreatic islets

Growth Properties:

Morphology: Epitheloid

Growth Medium: RPMI-1640 + 2mM Glutamine + 10% FCS

Subculturing Procedure: Split sub-confluent cultures (70-80%) 1:8 to 1:10 i.e. seeding at 2-4 x 10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. Population doubling approx 20hrs. At confluence 100,000 cells/cm² can be expected.

Release Conditions: Yes – commercial organisations are required to complete the ‘Cell Line Release Authorisation for Research Use in Commercial Organisations’ release conditions form.

Depositor:

Originator:

References: McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O’Harte FP, Yoon TW, Swanston-Flatt SK, Flatt PR. 1996 Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion Diabetes. 45(8):1132-40. PMID: 8690162

Hyperlink to ECACC Cell Line Data Sheet: 10033003